Phenotyping patterns of left ventricular remodeling and hypertrophy in systemic hypertension by cardiac magnetic resonance (CMR)

Methods Consecutive patients referred from our tertiary hypertension clinic, who underwent CMR at 1.5T, were included. Exclusion criteria included patients with clinical or CMR evidence of concomitant pathology (e.g. moderate-severe aortic stenosis) which may confound remodeling/hypertrophy pattern. Indexed LVM (iLVM), including papillary muscle mass by blood pool thresholding, indexed LV enddiastolic volume (iEDV) and ejection fraction (EF) were calculated using established CMR methods and normalized to body surface area. Values out-with the 95 confidence intervals of established CMR normal reference values were considered abnormal. Mass : volume ratio (M/ V) >1.12 for men and >1.14 for women was defined as abnormal, in accordance with previous literature. The phenotypes of ventricular remodeling and hypertrophy were defined as either normal, concentric remodeling, asymmetric remodeling, concentric hypertrophy, asymmetric hypertrophy, eccentric hypertrophy or decompensation depending on the constellation of iLVM, iEDV, M/V, asymmetric thickness (>13mm and >1.5 fold opposing wall) and EF Results One hundred and twenty three (n=123) patients were analysed. The prevalence of different phenotypical responses were as follows: normal (42.3%), concentric remodeling (6.5%), asymmetric remodeling (5.7%), concentric hypertrophy (12.2%), asymmetric hypertrophy (17.9%) eccentric hypertrophy (8.9%) and decompensation (6.5%). The demographic and CMR characteristics of the different types of remodeling and hypertrophy are described in Figure 1. There was no predilection of remodeling/hypertrophic pattern according to hypertension type. 12.2% of our cohort had normal iLVM but demonstrated concentric/asymmetric remodeling. Subgroup analysis by remodeling (n=15) versus hypertrophy (n=22) revealed no significant difference in age (62±9.4 vs 55.1±12.4 years, p=0.0598), gender (% male 74.4% vs 68.2%, p=0.999), BMI (30.9±3.0 vs 30.1±4.9 kg/m, p=0.5836), degree of hypertension (SBP 179.9±31.3 vs 176.8±24.7 mmHg, p=0.7407 and DBP 98.4±11.4 vs 95.7±14.8 mmHg, p=0.5557) or prevalence of potentially remodeling modifying medication (ACEi/ARB 80.0% vs 77.3%, p=0.999).